News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

aRigen Inc., Japanese Bioventure Company, Announces Start Of US Clinical Study Of Novel Anti-Staph Antibiotic By Catalyst CRO



10/19/2005 5:11:32 PM

aRigen Inc. (aRigen) a privately held, bioventure company headquartered in Tokyo, Japan announced initiation of their Phase I, single dose study of WAP 8294A2 (WAP). WAP has a unique mechanism of action and potent antimicrobial efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and other drug resistant strains.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES